Sign in
PH

PetVivo Holdings, Inc. (PETV)·Q3 2024 Earnings Summary

Executive Summary

  • Revenue accelerated: $0.60M in Q3 FY2024 (+16.9% YoY) on initial Covetrus contributions and stronger MWI/direct sell-through; net loss improved to $(1.75)M vs $(2.31)M YoY, aided by $0.38M other income from extinguishment of payables .
  • Channel expansion: Covetrus added in late December (top-2 U.S. distributor alongside MWI), a key go-to-market milestone; management highlighted rising awareness and KOL support driving small-animal interest in Spryng .
  • Cost discipline and mix: Operating expenses fell YoY to $2.55M (from $2.61M), while cost of sales declined YoY, supporting improved gross profit; operating loss narrowed to $(2.13)M from $(2.32)M .
  • Liquidity watch: Cash was $0.08M at 12/31/23 with a working capital deficit of $(0.17)M; the company raised ~$1.25M on Feb 2 to bolster liquidity near-term .
  • Estimates context: S&P Global consensus (EPS, revenue) could not be retrieved at time of query due to an API limit; no estimate comparison shown (attempted to pull quarterly EPS and revenue consensus via S&P Global; request failed).

What Went Well and What Went Wrong

  • What Went Well

    • Distribution reach expanded to Covetrus (non-exclusive), giving PETV the two largest U.S. animal health distributors (MWI and Covetrus) selling Spryng .
    • Clinical validation momentum: Ethos CCL study achieved all endpoints (pain, lameness, QoL) in 39 dogs; first cohort in hip OA study showed favorable results (VOS presentation), supporting small-animal adoption narrative .
    • Growing awareness and KOL support: Management cited “strong movement of positive awareness” among small-animal vets, peer-reviewed articles (e.g., Dr. Tammy Grubb) endorsing first-line use and as an NSAID alternative, and multiple podium mentions at conferences .

  • What Went Wrong

    • Liquidity tightness: Cash of $0.08M and working capital deficit at quarter-end required subsequent capital raise (~$1.25M on Feb 2), underscoring funding dependence .
    • Scale vs. opex: Revenues of ~$0.60M remain small relative to operating expenses of $2.55M, keeping operating loss elevated despite YoY improvement .
    • Limited visibility: No formal financial guidance issued; growth hinges on distributor sell-through, clinic adoption, and clinical data cadence rather than quantified outlook .

Financial Results

Sequential performance (FY2024)

MetricQ1 FY2024Q2 FY2024Q3 FY2024
Revenue ($)$117,183 $207,366 $595,891
Cost of Sales ($)$82,269 $140,913 $183,087
Gross Profit ($)$34,914 $66,453 $412,804
Operating Expenses ($)$2,928,491 $3,010,796 $2,546,428
Operating Loss ($)$(2,893,577) $(2,944,343) $(2,133,624)
Other (Income)/Expense ($)$0 $(716,810) $383,776
Net Loss ($)$(2,893,577) $(3,661,153) $(1,749,848)
EPS (Basic & Diluted)$(0.25) $(0.28) $(0.12)

YoY comparison (Q3)

MetricQ3 FY2023Q3 FY2024
Revenue ($)$510,109 $595,891
Cost of Sales ($)$223,687 $183,087
Gross Profit ($)$286,422 $412,804
Operating Expenses ($)$2,605,240 $2,546,428
Operating Loss ($)$(2,318,818) $(2,133,624)
Other Income ($)$7,200 $383,776
Net Loss ($)$(2,311,618) $(1,749,848)
EPS (Basic & Diluted)$(0.23) $(0.12)

Revenue mix by channel

ChannelQ3 FY2023Q2 FY2024Q3 FY2024
MWI ($)$456,502 $143,606 $439,922
Covetrus ($)$0 $0 $106,074
Direct to Clinics ($)$53,607 $63,760 $49,265

Balance sheet KPIs (end of period)

MetricQ1 FY2024 (6/30/23)Q2 FY2024 (9/30/23)Q3 FY2024 (12/31/23)
Cash & Equivalents ($)$218,978 $55,254 $80,085
Accounts Receivable ($)$47,108 $155,888 $518,686
Inventory ($)$406,030 $434,080 $467,467
Working Capital ($)$(448,561) $100,517 $(169,236)

Notes:

  • Q3 liquidity subsequently bolstered by ~$1.25M raised on Feb 2, 2024 .
  • Management also cited $519k accounts receivable at 12/31/23 on the call (balance sheet shows ~$518.7k) .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
All financial metricsFY2024/near-termNone issuedNone issued—

Note: No quantitative guidance was provided in the Q3 press release or discussed as formal ranges on the call; management focused on distribution, clinical data, and adoption drivers rather than issuing financial targets .

Earnings Call Themes & Trends

TopicQ1 FY2024 (Aug 2023)Q2 FY2024 (Nov 2023)Q3 FY2024 (Feb 2024)Trend
Distribution/Go-to-marketEmphasis on MWI; building ammo for small-animal push via studies and podiums .Continued MWI; prepping for major shows; sell-through focus .Added Covetrus (late Dec), now with top-2 distributors; awareness improving .Positive channel expansion and awareness.
Clinical evidence8 studies in flight; expecting multiple small-animal readouts 3–4 months .Ethos CCL final results positive; tolerance studies to be released as white papers .Positive hip OA cohort (VOS), more canine/equine studies targeted for 2024 .Strengthening data package.
Small-animal adoption90% of sales equine; aiming for first-use positioning; KOL strategy .Strong vet interest at shows; 70%+ recognition anecdote .“Strong movement of positive awareness”; KOLs and peer-reviewed articles cited .Improving adoption narrative.
Macro/pet industry—Q&A: pet ownership down; micro-cap/pet peer pressure; tax-loss selling noted .— (no macro emphasis in prepared remarks) .Macro headwinds acknowledged earlier, not central in Q3.
Financing/Liquidity$2.1M raised Apr; $2.325M net raised post-Q1 (Jul/Aug) .$2.35M raised (convertible/direct); $1.07M ATM post-Q2 .~$1.25M raised Feb 2; cash $0.08M at 12/31 .Ongoing capital raises bridge operations.
Product positioning (NSAID alternative; first-line)Dr. Tammy Grubb peer-reviewed article supports first-line use and NSAID alternative .Reiterated in narrative .Reiterated; KOL momentum and podium mentions .Consistent messaging.

Management Commentary

  • Strategic distribution: “The addition of the vast distribution resources offered by Covetrus to the distribution resources offered by our other distribution partner, MWI Animal Health, arms PetVivo with the two largest animal health industry distributors in the United States selling Spryng” — John Lai, CEO .
  • Clinical validation: “The final results of the cranial cruciate disease study provided by Ethos indicated significant improvement in 39 dogs injected with Spryng. All primary and secondary clinical endpoints related to pain, lameness and quality of life were achieved” — John Dolan .
  • Adoption tailwinds: “We have recently witnessed a strong movement of positive awareness by small animal veterinary doctors of our product Spryng… numerous key opinion leaders [are] mentioning Spryng at conferences” — John Lai .
  • Near-term focus: Increased social media to highlight clinical outcomes and KOL endorsements to accelerate clinic adoption .

Q&A Highlights

  • The Q3 transcript content available reflects prepared remarks and the transition to Q&A, but does not capture detailed Q&A exchanges; no additional guidance clarifications were recorded in the accessible sections .
  • Prior quarter (Q2) Q&A themes: macro headwinds (pet ownership declines, micro-cap pressure, tax-loss selling) and catalysts (clinical data, major shows); management also discussed small-animal adoption timelines and broader market positioning .

Estimates Context

  • Attempted to retrieve S&P Global (Capital IQ) quarterly consensus for EPS and revenue (Q1–Q3 FY2024) to compare to actuals; request failed due to an API limit, so no estimate comparison is shown. If you want, we can rerun post-reset to add beat/miss analysis.
  • Without consensus data, we note results standalone: revenue grew YoY to $0.60M; net loss improved YoY to $(1.75)M, aided by $0.38M other income (extinguishment of payables) .

Key Takeaways for Investors

  • Channel catalyst: Covetrus onboarding alongside MWI meaningfully enlarges reach; watch for distributor sell-through and reorder cadence as the next proof point .
  • Data-driven adoption: Positive Ethos CCL and favorable hip OA cohort results plus KOL/podium exposure support small-animal first-use positioning; further 2024 readouts are key .
  • Operating leverage path: YoY improvement in gross profit and lower opex produced a narrower operating loss; sustained opex discipline and revenue scaling are needed to drive breakeven trajectory .
  • Liquidity risk remains: $0.08M cash at Q3 end and working capital deficit necessitated a ~$1.25M raise; continued access to capital is a monitoring item until operating cash burn materially improves .
  • Mix dynamics: Q3 revenue benefited from Covetrus debut and MWI strength; direct clinic sales were modest; broader clinic adoption and small-animal penetration are the secular growth levers .
  • Narrative that could move the stock: evidence of accelerating clinic reorder rates via distributors, additional peer-reviewed publications, and quantifiable small-animal uptake could be inflection catalysts; conversely, funding gaps or slower distributor sell-through would be negative .

Sources: Q3 FY2024 press release and 8-K (including financial statements) ; Q3 FY2024 earnings call transcript ; Q2 FY2024 press release/8-K and call ; Q1 FY2024 press release/8-K and call .